Contineum Therapeutics, Inc.CTNMEarnings & Financial Report
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class and best-in-class targeted therapies to address unmet medical needs in autoimmune, inflammatory, and fibrotic diseases. It operates across North American and global biotech research networks, advancing multiple pipeline candidates through early to mid-stage clinical trials.
CTNM Q3 FY2024 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-13.0M
Net Profit
$-10.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.40
Contineum Therapeutics, Inc. Q3 FY2024 Financial Summary
Contineum Therapeutics, Inc. reported revenue of $0 for Q3 FY2024, with a net profit of $-10.3M (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-10.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2024 |
Contineum Therapeutics, Inc. Quarterly Revenue & Net Profit History
Contineum Therapeutics, Inc. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $0 | — | $-10.3M | N/A |
| Q2 FY2024 | $0 | — | $-9.0M | N/A |
Income Statement
| Q2 2024 | Q3 2024 | |
|---|---|---|
| Revenue | $0 | $0 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | |
|---|---|---|
| Assets | $221.4M | $216.0M |
| Liabilities | $3.9M | $5.8M |
| Equity | $217.5M | $210.2M |
Cash Flow
| Q2 2024 | Q3 2024 | |
|---|---|---|
| Operating CF | $-8.5M | $-6.2M |